CEL-SCI (CVM) Surges as Investors Revisit 10-Year Phase 3 Data and Multikine’s 14.1% OS Benefit
Cel-Sci Corporation (NYSE:CVM) is a long-established biotechnology company built on a singular mission: to transform the treatment of…
Browsing Tag